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Abstract.  
Traditional vaccines against viruses are designed to target their surface proteins, i.e., antigens, 
which can trigger the immune system to produce specific antibodies to capture and neutralize 
the viruses. However, viruses often evolve quickly, and their antigens are prone to mutations to 
avoid recognition by the antibodies (antigenic drift). This limitation of the antibody-mediated 
immunity could be addressed by the T-cell mediated immunity, which is able to recognize 
conserved viral HLA peptides presented on virus-infected cells. Thus, by targeting conserved 
regions on the genome of a virus, T-cell epitope-based vaccines are less subjected to mutations 
and may work effectively on different strains of the virus. Here we propose a personalized 
workflow to identify an optimal set of T-cell epitopes based on the HLA alleles and the 
immunopeptidome of an individual person. Specifically, our workflow trains a machine learning 
model on the immunopeptidome and then predicts HLA peptides from conserved regions of a 
virus that are most likely to trigger responses from the person’s T cells. We applied the workflow 
to identify T-cell epitopes for the SARS-COV-2 virus, which has caused the recent COVID-19 
pandemic in more than 100 countries across the globe.  
INTRODUCTION 
Since Louis Pasteur experimented with live attenuated cholera vaccine and inactivated anthrax 
vaccine at the end of the 19th century, these methods of producing vaccines have saved billions 
of lives and are still in use today. Such vaccines are designed to stimulate the host immune 
system to elicit specific antibodies that bind to the corresponding antigens on the surface of a 
virus and neutralize the virus. In addition, memory B cells are formed to provide long-term 
protection by remembering the antigens and quickly producing the antibodies in future re-
exposure to the same virus. However, both antibodies and memory B cells are specific to the 
antigens, and the later are prone to mutations to avoid recognition by the former (so called 
“antigenic drift”). Once a mutated virus escapes the antibodies and infects the host cells, it now 
depends on the T-cell mediated immunity to fight against the virus. Inside the infected cells, viral 
proteins are processed into short peptides, which are then loaded onto MHC proteins (MHC: 
major histocompatibility complexes). Subsequently, the MHC-peptide complexes are presented 
on the surface of infected cells for recognition by specific T cells. Activated CD8+ T cells then 
recognize and clear the infected cells. Similar to the antigen-antibody association, the T-cell 
immunity also depends strictly on the MHC-peptide complexes. MHC proteins are encoded by 
human leukocyte antigen (HLA), a gene complex that is located among the most genetically 
variable regions on the human genome. HLA alleles essentially change from one individual to 
another, and each allele can only present a certain set of peptides. HLA peptides that can be 
presented on the surface of infected cells and recognized by T cells are called T-cell epitopes. 
Last but not least, for a vaccine to provide long-term and robust protection, it is essential to 
identify T-cell epitopes that originate from conserved regions of the virus. Given the extremely 
high specificity of the MHC-peptide-T cells mechanism, a personalized approach is desirable to 
precisely identify optimal conserved T-cell epitopes for each individual person. 
As of March 11, 2020, COVID-19 has been spreading to over 100 countries on all continents. 
Within about three months since December 2019, the number of infected cases has soared to 
more than 120,000 and the number of deaths has surpassed 4,000 worldwide. While the 
epidemic initially started in China with majority of infected cases (~70%), massive clusters of 
thousands of cases have broken out in several other countries, including Italy, Iran, South 
Korea, France, Spain, Germany, and the United States. The outbreak has also crippled the 
global economy, causing the worst chaos and market rout since the financial crisis in 2008. A 
potent vaccine is the only solution to this pandemic.  
Traditional vaccine designs may have limitations when applied to COVID-19. While having less 
fatality rate, the number of infected cases of COVID-19 in just three months has exceeded 10 
times the total number of SARS and MERS, two other viruses from the corona family that have 
caused recent outbreaks in 2003 and 2012. This very high level of contagious may suggest that 
COVID-19 is able to mutate quickly for adaptation, probably even more than influenza. Thus, 
vaccines based on antibodies and memory B cells may become obsolete soon after introduced. 
For instance, in the case of influenza, we have to inoculate people with an updated vaccine 
every year, which is often only partially effective [1]. Traditional universal vaccines may also 
cause autoimmune diseases such as multiple sclerosis, type 1 diabetes, systemic lupus [2].  
T-cell epitope-based vaccines have been explored in recent years thank to their capability of 
targeting conserved epitopes and hence providing long-term protection against different strains 
of viruses [17]. Using epitopes as vaccine ingredients also has the safety advantage than using 
attenuated or inactivated viruses. T-cell epitope-based vaccines have been developed for 
malaria, HIV, Hepatitis C virus, influenza, and tuberculosis (BCG), with various success rates 
[4]. While BCG induces T-cell responses to a large number of antigens, for most diseases, the 
vaccines depend only on a few selected epitopes [3]. A recent study on influenza by Auladell et 
al. suggests that CD8+ T cell response has an emerging role in influenza protection [14]. 
To our knowledge, while neoantigens have been used for cancer immunotherapy vaccines 
[19,20], all prior works on T-cell virus vaccines only involved peptides from the pathogen 
proteins but not neoantigens that are actually presented by the HLA class I complex (and their 
subtypes) determined by mass spectrometry. These neoantigens are not universal for all HLA 
types and are not necessarily obtained directly from the pathogen proteins, as they could be cis- 
and trans-spliced peptides or from noncoding regions [9,5]. Thus, we propose a personalized 
workflow to use mass spectrometry together with our recent deep learning models [7,8,10] to 
directly identify conserved T-cell epitopes on the surface of virus-infected cells. 
RESULTS 
A workflow for the T-cell vaccine design 
Figure 1 describes our workflow for HLA-specific anti-viral CD8+ T-cell peptide-based vaccine 
design. This workflow combines our cancer immunotherapy platform [6] and parts from [16]. The 
details of each step in the workflow are explained in the following: 
1. 108 sick cells are obtained from patient blood sample. 
2. Genome sequencing gives 6 HLA types, as well as TCR sequences. 
3. Immunopeptidome is obtained by mass spectrometry and analyzed with PEAKS X 
[10] database search using no-enzyme option. The immunopeptidome is used to re-
train DeepNovo [7,8] for each HLA subtype on the left.  
4. Personalized DeepNovo model is used to analyze the mass spectrometry data again 
to find peptides that were missing from the PEAKS X database search (these are cis-
or trans-spliced peptides). 
5. For each of the 6 HLA types, this personalized approach enables comprehensive 
and accurate identification of neoantigens. 
6. Effective neoantigens are selected for each HLA allele. 
Previous research in SARS-CoV suggests that spike (S) protein is the main antigenic 
component responsible for inducing the host immune responses. Thus, it is an important target 
for vaccine and antiviral development [12]. Promising results for vaccines developed based on 
the full sequence of S protein have been reported on mouse models [13].  
Without mass spectrometry data, just using the computational part of the workflow in Figure 1, 
we can identify potential target peptides for developing an epitope-based vaccine against the 
nCov-2019. Table 1 reports optimal T-cell epitopes for each of the top 20 most frequent HLA 
class I alleles in Chinese population [15]. Following [16], we used NetCTLpan 1.1 server to find 
potent target peptides from the S protein of nCoV-2019 (GenBank: MN908947.3). The 
NetCTLpan tool integrates peptide MHC binding prediction, proteasomal C terminal cleavage 
and TAP transport efficiency. A combined rank score is given for each pair of peptide and HLA 
allele. This score represents the rank of prediction score to a set of 1,000,000 random natural 9-
mer peptides. We filtered NetCTLpan-predicted peptides with a rank score threshold of 2%. 
After filtering, 177 peptides remained, and on average, each allele had 23 candidate peptides. 
Alignment of those peptides against the Uniprot human database showed that none of them 
was self-peptide. Next, we applied the IEDB immunogenicity prediction tool to predict the 
immunogenicity of those 177 peptides. The median of immunogenicity scores was used as a 
threshold to select the top 50% peptides. Table 1 shows the top 3 candidates and their 
corresponding predicted immunogenicity score for each included allele. The candidate peptides 
were ranked by the MHC score predicted by NetCTLpan. As we can see from the results, there 
are 13 unique peptides among 15 candidate peptides reported for the top 5 most frequent 
alleles. This shows that different HLA alleles “prefer” different viral peptides with different 
binding affinities. This fact has three implications: 
1. An epitope-based vaccine should be designed specifically for each individual person 
according to his/her HLA alleles.  
2. Each person’s response to the virus infection might be correlated to his/her HLA 
alleles (in fact, this diversity is part of the natural selection of a species to survive). 
This hypothesis may have consequences in treatment of patients and prevention. 
3. Generating such optimal CD8+ T cells may have therapeutic consequences, as early 
and rapid response of highly efficient T cells could help to control the virus 
multiplications hence preventing cytokine storm in the lung. 
 A similar analysis was performed on the nucleocapsid protein and the results are reported in 
Table 2. HLA class 1 has three loci A (68 common alleles), B (125 common alleles), C (44 
common alleles), thus a total of 237 common alleles. We propose to extend Tables 1 and 2 from 
20 alleles to all 237 common alleles. The predicted T-cell epitopes can be further verified by 
mass spectrometry and immune response assays.  
Figure 2 gives two methods of applying the vaccine, modulo methods of selecting proper 
adjuvants such as dendritic cells. To design an epitope-based vaccine for each person, we first 
identify the HLA alleles. Then based on the allele-epitope associations, we can assemble an 
HLA-specific vaccine as depicted in Figure 2a. Given the current limited data (only the genome 
of the virus), our candidate peptides are predicted solely from the HLA alleles. When the 
immunopeptidomics data is available, we can train a personal deep learning model on the 
immunopeptidome of each individual person to improve the epitope prediction.  
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Figure Legends 
Figure 1. Workflow for obtaining data, training our prediction models, and obtaining neoantigens 
for each HLA allele. 
Figure 2. Vaccination workflow. (a) Simple vaccination method. (b) Fully personalized 
vaccination. 

(a) (b)
Table 1. Top 3 candidate peptides from S protein.
HLA alleles
Allele frequency 
in Chinese population
Candidate 1 Candidate 2 Candidate 3
HLA-A*11:01 0.277 GVYFASTEK ASANLAATK VTYVPAQEK
HLA-A*24:02 0.172 QYIKWPWYI IAIPTNFTI PYRVVVLSF
HLA-C*01:02 0.169 FVFLVLLPL RGWIFGTTL IAIPTNFTI
HLA-B*40:01 0.149 AEVQIDRLI KEIDRLNEV FERDISTEI
HLA-C*03:04 0.128 WTFGAGAAL FVFLVLLPL FTISVTTEI
HLA-C*08:01 0.126 WTFGAGAAL FQFCNDPFL IAIPTNFTI
HLA-A*33:03 0.115 SVYAWNRKR YNYLYRLFR GTHWFVTQR
HLA-B*46:01 0.115 FTISVTTEI STQDLFLPF FVSNGTHWF
HLA-A*02:03 0.108 FIAGLIAIV VLNDILSRL VVFLHVTYV
HLA-A*02:07 0.094 YLQPRTFLL FIAGLIAIV VVFLHVTYV
HLA-B*58:01 0.089 RSFIEDLLF LAGTITSGW IAIPTNFTI
HLA-C*03:02 0.087 STQDLFLPF FVFLVLLPL QSAPHGVVF
HLA-B*13:01 0.082 YEQYIKWPW IAIPTNFTI FERDISTEI
HLA-B*15:02 0.071 WMESEFRVY LPFNDGVYF QLTPTWRVY
HLA-B*38:02 0.071 YQPYRVVVL SQSIIAYTM YLQPRTFLL
HLA-A*02:01 0.053 YLQPRTFLL FIAGLIAIV FQFCNDPFL
HLA-B*51:01 0.05 IPTNFTISV LPFFSNVTW IAIPTNFTI
HLA-B*15:01 0.044 WMESEFRVY STQDLFLPF GTITSGWTF
HLA-C*04:01 0.044 RGWIFGTTL SNVTWFHAI IAIPTNFTI
HLA-C*03:03 0.041 WTFGAGAAL FVFLVLLPL FTISVTTEI
Table 2. Top 3 candidate peptides from N protein.
HLA alleles
Allele frequency in 
Chinese population
Candidate 1 Candidate 2 Candidate 3
HLA-A*11:01 0.277 KTFPPTEPK LSPRWYFYY
HLA-A*24:02 0.172 YYRRATRRI KHWPQIAQF TWLTYTGAI
HLA-C*01:02 0.169 SPRWYFYYL NTASWFTAL TPSGTWLTY
HLA-B*40:01 0.149
HLA-C*03:04 0.128 NTASWFTAL SPRWYFYYL
HLA-C*08:01 0.126 NTASWFTAL SPRWYFYYL LTYTGAIKL
HLA-A*33:03 0.115 IGYYRRATR NVTQAFGRR GYYRRATRR
HLA-B*46:01 0.115 NTASWFTAL
HLA-A*02:03 0.108 GMSRIGMEV
HLA-A*02:07 0.094
HLA-B*58:01 0.089 LSPRWYFYY KHWPQIAQF
HLA-C*03:02 0.087
HLA-B*13:01 0.082
HLA-B*15:02 0.071 NTASWFTAL TPSGTWLTY
HLA-B*38:02 0.071 KHWPQIAQF
HLA-A*02:01 0.053 GMSRIGMEV
HLA-B*51:01 0.05 NPANNAAIV SPRWYFYYL LPNNTASWF
HLA-B*15:01 0.044
HLA-C*04:01 0.044 SPRWYFYYL TWLTYTGAI YYRRATRRI
HLA-C*03:03 0.041 NTASWFTAL SPRWYFYYL
